A5100452879- Breast Cancer Treatment Studies
- Advanced Breast Cancer Therapies
- MicroRNA in disease regulation
- HER2/EGFR in Cancer Research
- Circular RNAs in diseases
- Cancer Treatment and Pharmacology
- Breast Lesions and Carcinomas
- Cancer Risks and Factors
- Cancer-related molecular mechanisms research
- Global Cancer Incidence and Screening
- Cancer Cells and Metastasis
- Cancer Genomics and Diagnostics
- Epigenetics and DNA Methylation
- Cancer Immunotherapy and Biomarkers
- Cancer-related Molecular Pathways
- Peptidase Inhibition and Analysis
- Cancer Diagnosis and Treatment
- RNA modifications and cancer
- Cancer, Lipids, and Metabolism
- Neutropenia and Cancer Infections
- Estrogen and related hormone effects
- Histone Deacetylase Inhibitors Research
- Monoclonal and Polyclonal Antibodies Research
- Breast Implant and Reconstruction
- Cell Adhesion Molecules Research
Fourth Hospital of Hebei Medical University
2016-2025
Hebei Medical University
2016-2025
Taian City Central Hospital
2025
Jinzhou Medical University
2024
Hospital of Hebei Province
2018-2024
Chinese PLA General Hospital
2020-2022
Kliniken Essen-Mitte
2021
Zhejiang Cancer Hospital
2013-2021
University of Chinese Academy of Sciences
2020
Beihai People's Hospital
2020
In the phase III IMpassion130 trial, combining atezolizumab with first-line nanoparticle albumin-bound-paclitaxel for advanced triple-negative breast cancer (aTNBC) showed a statistically significant progression-free survival (PFS) benefit in intention-to-treat (ITT) and programmed death-ligand 1 (PD-L1)-positive populations, clinically meaningful overall (OS) effect PD-L1-positive aTNBC. The KEYNOTE-355 trial adding pembrolizumab to chemotherapy aTNBC similar PFS effects. IMpassion131...
Metastasis and recurrence are the leading cause of mortality due to breast cancer, but underlying mechanisms still poorly understood. Understanding cancer metastasis mechanism is important for early diagnosis treatment cancer. The seeding growth cells at sites distinct from primary tumor a complex multistage process. Recently, it has been reported that epithelial-mesenchymal transition (EMT) mesenchymal-epithelial (MET) main metastasis. During EMT, carcinoma shed their differentiated...
Developing guidelines for the diagnosis and treatment of common cancers in China based on evidence-based practice, availability products, up-to-date advances precision medicine is one basic tasks Chinese Society Clinical Oncology (CSCO).In recent years, medical resources has become a major concern clinical guidelines, which particularly important developing countries or socioeconomically diverse territories.China world's largest country, with large territory uneven economic academic...
Abstract Objective To assess the efficacy and safety of pyrotinib (an irreversible pan-HER (human epidermal growth factor receptor) inhibitor), trastuzumab, docetaxel compared with placebo, for untreated HER2 positive metastatic breast cancer. Design Randomised, double blind, placebo controlled, multicentre, phase 3 trial. Setting 40 centres in China between 6 May 2019 17 January 2022. Participants 590 female patients (median age 52 (interquartile range 46-58) years) Interventions Eligible...
Abstract Circular RNA ciRS-7 has been reported to act as a competing endogenous (ceRNA) of the miRNA miR-7, resulting in reduced miR-7 activity and increased miR-7–targeted transcripts. However, it is unknown if harbors other miRNAs with regulatory roles triple-negative breast cancer (TNBC). The present study determined that expression TNBC clinical specimens representative cells significantly higher than subtypes. Functionally, downregulation inhibited cell migration invasion cells....
There are limited nationwide data regarding breast cancer surgery in China. The Chinese Anti-Cancer Association's Committee of Breast Cancer Society and the Surgeons conducted a survey to examine use barriers associated with surgical options among patients cancer.Surveys were sent via e-mail directors 110 centers that performed at least 200 operations 2017. electronic questionnaire contained 183 questions covered six aspects, including demographic information about hospitals surgeons,...
1102 Background: MRG002 is a novel HER2-targeted ADC, composed of sugar-modified trastuzumab, MMAE payload and cleavable vc-linker. was effective in HER2-low expressing breast cancer preclinical studies. Hence, we conducted the phase II study to evaluate safety anti-tumor efficacy HER-low cancer. Methods: HER2 low tumor expression determined by central lab had be immunohistochemistry (IHC)1+ or 2+/ISH-. Eligible patients advanced/metastatic that failed standard therapies. administered...
Breast cancer treatment has profoundly improved in China recently. However, trends disparities and transitions of early-stage between the US are not well known.
Totally implantable venous access port systems (TIVAPS) are widely used in breast cancer patients. However, complications frequent and may necessitate device replacement or removal, resulting additional patient stress treatment delays. The aim of this study was to investigate possible risk factors for complications. A total 2,996 consecutive female patients, with a median age 50.2 years (range, 21.2-85.5 years) were enrolled observational, single-centre between December, 2008 April, 2014....
BackgroundCancer patients had been profoundly affected by the outbreak of COVID-19 especially after quarantine restrictions in China. We aimed to explore treatment changes and delays early breast cancer (EBC) during first quarter 2020.MethodsWe did this retrospective, multicentre, cohort study at 97 centres EBC who received regardless preoperative therapy, surgery or postoperative therapy 2020 were included.Findings8397 eligible with a median age 50 (IQR 43–56). 0·2% (15/8397) confirmed as...
PURPOSE The OlympiA randomized phase III trial compared 1 year of olaparib (OL) or placebo (PL) as adjuvant therapy in patients with germline BRCA1/2, high-risk human epidermal growth factor receptor 2–negative early breast cancer after completing (neo)adjuvant chemotherapy ([N]ACT), surgery, and radiotherapy. patient-reported outcome primary hypothesis was that OL-treated may experience greater fatigue during treatment. METHODS Data were collected before random assignment, at 6, 12, 18, 24...
Trastuzumab is a key component of therapy for human epidermal growth receptor 2 (HER2) positive breast cancer. Because real-world data are lacking, the present research was conducted to evaluate actual use and effectiveness trastuzumab in real world China.Inpatients with HER2 invasive cancer from 13 hospitals Eastern China (2010-2015, n = 1,139) were included this study. We aimed assess potential efficacy research.Of 1,017 patients early stage (EBC), 40.5% (412/1,017) received therapy....
Obesity is a consideration in the pharmacologic intervention for estrogen receptor (ER) positive (ER+) breast cancer risk. Body mass index (BMI) and waist/hip ratio (WHR) have demonstrated different effects on risk relation to status, but results been inconsistent. Furthermore, situation Chinese women remains unclear.We conducted case-control study including 1,439 cases Northern Eastern China. Both ER progesterone (PR) statuses were available 1,316 cases. Associations between body...
MicroRNAs (miRs) are a small non-coding RNA family with length of 18-22 nucleotides. They able to regulate gene expression by either triggering target messenger degradation or inhibiting mRNA translation. Enhancer zeste homolog 2 (EZH2) is the core enzymatic subunit polycomb repressor complex and responsible for trimethylation histone 3 on lysine 27 (H3K27me3); it also silence bundle tumor suppressor genes through promoter binding. However, little known regarding effect miR‑92b cell...
Zinc finger E-box binding homeobox 1 (ZEB1) has been widely recognized as an important driver of tumor growth and metastasis. However, nothing is known about ZEB1-regulated circular (circ)RNAs in cancer. In the current study, we evaluated function a novel circRNA derived from WWC3 gene locus, circWWC3 breast cancer progression. We found that ZEB1 upregulated expression but not linear mRNA expression. highly expressed tissues associated with poor prognosis patients. Silencing significantly...
To examine the impact of a clinical decision support system (CDSS) on breast cancer treatment decisions and adherence to National Comprehensive Cancer Center (NCCN) guidelines.